Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus

Clin Infect Dis. 1993 Oct;17(4):625-7. doi: 10.1093/clinids/17.4.625.

Abstract

We describe two cases of visceral leishmaniasis in patients infected with human immunodeficiency virus (HIV); both cases were resistant to antimony compounds but were cured with liposomal amphotericin B, with no significant toxicity. A review of the previous reported cases of antimony-resistant visceral leishmaniasis in HIV-infected patients confirmed the effectiveness of treatment with liposomal amphotericin B, which directly targets infected macrophages and reaches high levels in plasma and tissue.

Publication types

  • Case Reports
  • Review

MeSH terms

  • AIDS-Related Opportunistic Infections / diagnosis
  • AIDS-Related Opportunistic Infections / drug therapy*
  • Adult
  • Amphotericin B / administration & dosage
  • Amphotericin B / therapeutic use*
  • Animals
  • Antiprotozoal Agents / pharmacology
  • Antiprotozoal Agents / therapeutic use*
  • Drug Carriers
  • Drug Resistance
  • Follow-Up Studies
  • HIV-1
  • Humans
  • Leishmania / drug effects
  • Leishmania / growth & development
  • Leishmaniasis, Visceral / diagnosis
  • Leishmaniasis, Visceral / drug therapy*
  • Liposomes
  • Male
  • Meglumine / pharmacology
  • Meglumine / therapeutic use*
  • Meglumine Antimoniate
  • Organometallic Compounds / pharmacology
  • Organometallic Compounds / therapeutic use*

Substances

  • Antiprotozoal Agents
  • Drug Carriers
  • Liposomes
  • Organometallic Compounds
  • Meglumine
  • Meglumine Antimoniate
  • Amphotericin B